

Mean survival time by ordered fractions of population with censored data

Celia García-Pareja¹, Matteo Bottai¹

¹ Unit of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

E-mail for correspondence: `celia.garcia.pareja@ki.se`

Abstract: We propose a novel approach for estimating mean survival time in the presence of censored data, in which we divide the population under study into survival-ordered fractions defined by a set of proportions, and compute the mean survival time for each fraction separately. Our approach provides a detailed picture of the distribution of the time variable while preserving the appealing interpretation of the mean. Our measure proves to be of great use in applications, particularly those where we are able to detect differences in mean survival across groups for certain fractions of the population that would have been overlooked using other available methods.

Keywords: Quantiles; Ordered Data; Mean Survival; Censoring; Kaplan-Meier

1 Introduction

Survival data analysis methods are the cornerstone of a wide range of statistical applications. While mean survival time is of utmost relevance, e.g., in health economics (Paltiel et al., 2009) or oncology studies (Zhao et al., 2001), its estimation might be hindered in the presence of censoring, where the time variable is only observed until a certain quantile. In practice, censoring is almost always present, calling for specialised estimation techniques. Several approaches have been considered to overcome this problem, the most used amongst them, the restricted mean, computes mean survival time up to a specific cut-off time point (Irwin, 1949). Estimation of the restricted mean, however, might be heavily affected by the presence of censored observations, which will result in a loss of estimation accuracy. Moreover, clinical relevance and interpretation of restricted mean estimates remains unclear.

This paper was published as a part of the proceedings of the 33rd International Workshop on Statistical Modelling (IWSM), University of Bristol, UK, 16-20 July 2018. The copyright remains with the author(s). Permission to reproduce or extract any parts of this abstract should be requested from the author(s).

We present a novel mean survival measure based on observed quantiles that divides the population in ordered fractions in which the mean survival can be estimated separately. Interpretation of the estimates is straightforward, as they represent mean survival times for the specified fractions of the population. Similarly to the restricted mean, we estimate mean survival up to a specific cut-off point, that we set to the largest observed p -th fraction of population to experience the event of interest. Our approach exploits that the distribution of observed and censored events imposes differences in the estimation accuracy of specific quantiles, i.e., those that are close to observed events can be more precisely estimated than those located after the occurrence of censored events. Therefore, estimates for certain fractions can be really precise, which allows quantifying significant mean survival differences across groups, even in scenarios where state-of-the-art methods are unable to detect them.

2 Mean survival by ordered fractions

Let T be a non-negative random variable with $E[T] < \infty$ and let $S(\cdot)$ and $Q(\cdot)$ denote its survival and quantile functions, respectively. An expression for the expectation of T in terms of $Q(\cdot)$ is

$$\mu = E[T] = \int_0^\infty S(t)dt = \int_0^1 Q(p)dp. \quad (1)$$

Given a grid of proportions $\{\lambda_0, \lambda_1, \dots, \lambda_K\}$ with $\lambda_{k-1} < \lambda_k$ for all $k \in \{1, \dots, K\}$, we can divide μ into separate components as follows

$$\mu = \sum_{k=1}^K \mu_k, \text{ where } \mu_k = \int_{\lambda_{k-1}}^{\lambda_k} Q(p)dp, \lambda_0 = 0 \text{ and } \lambda_K = 1. \quad (2)$$

If we now weight each μ_k by its corresponding inverse proportion, we obtain

$$\bar{\mu}_k = \frac{\mu_k}{\lambda_k - \lambda_{k-1}},$$

where $\bar{\mu}_k$ is the mean survival time for a specific fraction of population delimited by $(\lambda_{k-1}, \lambda_k)$. For example, if we consider $(\lambda_0, \lambda_1) = (0, 0.5)$, $\bar{\mu}_1$ quantifies mean survival time for the first half of the population to experience the event of interest.

In the presence of a censoring variable C , when $Y = \min(T, C)$ is observed, the decomposition shown in (2) is of utmost convenience because λ_K can be set to the largest proportion of observed events, that is, the one corresponding to the last observed quantile. Note that when $\lambda_K < 1$, the mean survival time for the λ_K -th fraction of the population observed to experience the event, does not correspond to the restricted mean computed up

to the last observed quantile $y^* = Q(\lambda_K)$. Indeed, while

$$\bar{\mu}_K = \frac{1}{\lambda_K} \int_0^{\lambda_K} Q(p) dp$$

can be easily interpreted in terms of the population under study, the corresponding

$$\mu^* = \int_0^{y^*} S(y) dy,$$

does not prove as informative.

3 Estimation and simulation results

In the presence of censoring, estimation of μ_k is possible via the Kaplan-Meier estimator of the underlying survival function, $\hat{S}(\cdot)$. Given $\hat{S}(\cdot)$ and the grid of proportions $\{\gamma_0, \gamma_1, \dots, \gamma_K\} = \{1 - \lambda_0, 1 - \lambda_1, \dots, 1 - \lambda_K\}$, an estimator for μ_k follows easily from equations (1) and (2), with

$$\begin{aligned} \widehat{\mu}_k &= \sum_{j=1}^{J_k} y_j [\min\{\hat{S}(y_{j-1}), \gamma_{k-1}\} - \max\{\hat{S}(y_j), \gamma_k\}] \\ &= \sum_{j_k=1}^{J_k} \hat{Q}(p_j)(p_j - p_{j-1}), \end{aligned}$$

where y_j denote observed event times such that $\hat{S}(y_j) \in [\gamma_k, \gamma_{k-1}]$ for all $j \in \{1, \dots, J_k\}$, and $\hat{S}(y_0) \geq \gamma_{k-1}$ and $\hat{S}(y_{J_k}) \leq \gamma_k$. In this case, we obtain a step-wise constant estimator of the quantile function $\hat{Q}(\cdot)$, in which observed times y_j play the role of estimated quantiles $\hat{Q}(p_j)$ of order $p_j = \hat{S}(y_j)$.

We tested the performance of $\widehat{\mu}_k$ in different scenarios, all yielding analogous conclusions. In Table 1 we present results for a simulation study of 5,000 data sets with 200 samples each, generated from a time variable following a log-logistic distribution with scale $\alpha = 1$ and shape $\beta = 2$. The censoring variables were sampled independently from a uniform distribution in $(0, 7/3)$, yielding an average censoring rate of 50%. Estimated average upper and lower bounds for $\widehat{\mu}_k$ were computed integrating over equal precision confidence bands for the Kaplan-Meier estimator (Nair, 1984). We observed that our estimates' precision decreased with increasing k (that is, the bands widened with increasing k), which was expected, as the proportion of censored observations also increased with k and fewer events were observed. In this sense, one might say that some μ_k can be *more precisely* estimated than others, which proves highly useful in application settings.

TABLE 1. Results for 5,000 samples of 200 observations from a log-logistic model with scale $\alpha = 1$ and shape $\beta = 2$ with censoring variable uniform in $(0, 7/3)$, corresponding to an average censoring rate of 50%. True (μ_k) and average estimated $(\widehat{\mu}_k)$ values, with average lower $(\widehat{\mu}_k^L)$ and upper $(\widehat{\mu}_k^U)$ bounds for 5 fractions of population, % of simulations (nsim_k) in which $\widehat{\mu}_k$ could be computed and average number of observed events (d_k) are reported. The average bound marked with * had finite values in 75% of the simulations.

k	λ_k	μ_k	$\widehat{\mu}_k$	$\widehat{\mu}_k^L - \widehat{\mu}_k^U$	nsim _k	d _k
1	0.20	0.064	0.064	0.044 – 0.086	100%	34
2	0.40	0.131	0.132	0.101 – 0.175	100%	29
3	0.60	0.201	0.202	0.156 – 0.264*	100%	23
4	0.80	0.311	0.304	0.226 – ∞	70.7%	14
5	0.95	0.420	0.307	0.239 – ∞	5.80%	4

4 Application example: Survival after bone marrow transplant in lymphoma patients

We analysed data on 35 patients with lymphoma that received either an allogenic or an autologous bone marrow transplant, that is, they received marrow from either a compatible donor or their own after chemotherapy treatment and cleansing (Avalos et al., 1993). The aim of the study was to find differences between lymphoma-free survival after having received either type of transplant. After 2.5 years of follow-up, 26 patients had died or relapsed and the censoring rate was 25.7%. The estimated survival curves for both treatments are shown in Figure 1.

While restricted mean survival estimates did not detect any significant difference in mean survival between the allogenic and autologous transplant groups (restricted mean difference of 146.5 days, with 95% confidence interval $(-29.71, 322.7)$), our approach showed that among earlier failures that difference was actually significant. In particular, considering the weakest 10% of the patients, that is, the first 10% to die or relapse after receiving the transplant, mean survival difference was estimated at 32.15 days (95% CI $(13.98 - 50.31)$) favouring those who received the autologous transplant. In Table 2 we show the results of mean survival time differences after receiving a bone marrow transplant by deciles of population up to the 80th percentile (last fraction commonly observed in both groups). Our estimates could detect an improvement on lymphoma-free survival for the autologous transplant group amongst at least the weakest 20% of patients, providing a useful guide for effective decision-making.




FIGURE 1. Estimated Kaplan-Meier survival curves after bone marrow transplant for lymphoma patients that received allogeneic (solid line) or autologous (dashed line) transplant.

TABLE 2. Estimates for mean survival differences between allogeneic ($\widehat{\mu^0_k}$) and autologous ($\widehat{\mu^1_k}$) bone marrow transplants with bootstrapped 95% confidence intervals by ordered deciles of population.

k	λ_k	$\widehat{\mu^1_k} - \widehat{\mu^0_k}$	95% CI
1	0.1	32.15	13.98 – 50.31
2	0.2	36.72	2.843 – 70.60
3	0.3	26.23	–19.94 – 72.43
4	0.4	28.98	–40.51 – 98.48
5	0.5	32.80	–124.5 – 190.1
6	0.6	80.60	–1283 – 1444
7	0.7	349.4	–446.4 – 1145
8	0.8	441.4	–130.3 – 1013

5 Final remarks

Our approach for quantifying mean survival time takes advantage of the information contained in the data and deals with the censoring hurdle. Our proposed measures are easily interpretable, providing a useful alternative to the restricted mean, which poses interpretation difficulties. By dividing the study population into ordered fractions, the proposed method provides a detailed picture of the underlying probability distribution and can detect

mean survival differences across groups that are often undetected by other methods. Results from a simulation study show good performance of our proposed estimation strategy even in the presence of censoring, and support the idea that mean survival can be more accurately estimated in some fractions of the population. In the analysis of survival data after bone marrow transplant, our method detected differences in mean survival between given transplants for certain fractions of population, while those differences were overlooked when using restricted mean estimates instead.

Acknowledgments: This work was partially supported by the KID funding doctoral grant from Karolinska Institutet

References

- Avalos, B.R., Klein, J.L., Kapoor, N., Tutschka, P.J., et al. (1993). Preparation for Marrow Transplantation in Hodgkin’s and non-Hodgkin’s Lymphoma Using Bu/CY. *Bone Marrow Transplantation*, **12**, 133–138.
- Irwin, J. O. (1949). The Standard Error of an Estimate of Expectation of Life, with Special Reference to Expectation of Tumourless Life in Experiments with Mice. *Journal of Hygiene*, **47**, 188–189.
- Nair, V.N. (1984). Confidence Bands for Survival Functions with Censored Data: A Comparative Study *Technometrics*, **26**, 265–275.
- Paltiel A.D., Freedberg K.A., Scott C.A., Schackman B.R., Losina E. et al. (2009). HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness. *Clinical Infectious Diseases*, **48**, 806–815.
- Zhao Y., Zeng D., Socinski M.A., Kosorok M.R. (2011). Reinforcement Learning Strategies for Clinical Trials in non-Small Cell Lung Cancer. *Biometrics*, **67**, 1422–1433.